Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: Elacestrant, Onapristone; Drug
Lead sponsor: Context Therapeutics Inc.; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer
Interventions: AC699; Drug
Lead sponsor: Accutar Biotechnology Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Denver, Colorado • Orlando, Florida • Sarasota, Florida + 6 more

Conditions: Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Interventions: Infigratinib, Tamoxifen, Omnipaque 350, Iopamidol, Computed tomography (CT); Drug · Diagnostic Test
Lead sponsor: Jennifer Lee Caswell-Jin; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: everolimus, anastrozole, letrozole, tamoxifen citrate, fulvestrant, megestrol acetate; Drug
Lead sponsor: Emory University; Other
Eligibility: 19 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Breast Cancer
Interventions: Gedatolisib, Palbociclib, Letrozole, Fulvestrant; Drug
Lead sponsor: Celcuity Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more

Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Interventions: Giredestrant, Fulvestrant or an Aromatase Inhibitor (Physician Choice), LHRH Agonist; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Marietta, Georgia • Cleveland, Ohio • Tigard, Oregon

Conditions: Metastatic Breast Cancer
Interventions: Belzutifan, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Goodyear, Arizona • Beverly Hills, California • La Jolla, California + 11 more

Conditions: Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2- Breast Cancer, ESR1 Gene Mutation, ER Wildtype, Breast Neoplasms
Interventions: Capecitabine, Elacestrant; Drug
Lead sponsor: Kristina A. Fanucci; Other
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma, Cancer of the Breast, Cancer of Breast, Malignant Tumor of Breast, Breast Tumor
Interventions: NUV-422, Fulvestrant; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Anaheim, California • Fountain Valley, California • Canton, Ohio + 2 more

Conditions: Breast Cancer
Interventions: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole; Drug
Lead sponsor: Celcuity Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 22
States / cities: Duarte, California • Fullerton, California • Los Angeles, California + 19 more

Conditions: Breast Cancer
Interventions: Taselisib, Placebo, Fulvestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 16
States / cities: Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more

Conditions: Advanced Metastatic Breast Cancer
Interventions: Ribociclib, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 59 Years · Female only
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 35
States / cities: Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more

Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions: Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx); Drug · Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 61
States / cities: Daphne, Alabama • Auburn, California • Glendale, California + 54 more

Conditions: Advanced ER-Positive HER2-Negative Breast Cancer
Interventions: AZD9833, Fulvestrant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Long Beach, California • Fort Myers, Florida + 6 more

Conditions: Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer
Interventions: Palazestrant, Ribociclib, Alpelisib, Everolimus, Atirmociclib; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 14
States / cities: Gilbert, Arizona • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Breast Cancer
Interventions: Capecitabine, Exemestane, Everolimus; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 19
States / cities: Los Angeles, California • San Diego, California • Fort Myers, Florida + 15 more

Conditions: Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer
Interventions: G1T48, Palbociclib; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Beverly Hills, California • Stanford, California • Chicago, Illinois + 3 more

Conditions: Advanced Breast Cancer
Interventions: ARV-471, Fulvestrant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 87
States / cities: Encinitas, California • Fountain Valley, California • Fresno, California + 69 more

Conditions: Breast Cancer
Interventions: PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 218
States / cities: Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 135 more

Conditions: Breast Cancer
Interventions: Ribociclib, letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Sedona, Arizona • Long Beach, California • Charlotte, North Carolina + 3 more

Conditions: Advanced or Metastatic Breast Cancer
Interventions: PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 17
States / cities: Irvine, California • Los Angeles, California • Newport Beach, California + 9 more

Conditions: Breast Cancer
Interventions: ARV-471, ARV-471 in combination with palbociclib (IBRANCE®); Drug
Lead sponsor: Arvinas Estrogen Receptor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 16
States / cities: Palo Alto, California • San Francisco, California • Santa Monica, California + 12 more

Conditions: Breast Cancer
Interventions: [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant, Goserelin; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Search by objective public record fields.

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Phase II Study of Everolimus Beyond Progression

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer